Alberto Bessudo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alberto bessudo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alberto Bessudo Today - Breaking & Trending Today

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

/PRNewswire/ Laekna Therapeutics, an emerging innovative biotech company based in China s "Zhangjiang Pharma Valley" and New Jersey, USA, focusing on the. ....

United States , New Jersey , Yue Yong , Alberto Bessudo Encinitas , European Society For Medical Oncology , European Society , Medical Oncology , Phasei Dose Escalation Study , Metastatic Castration Resistant Prostate Cancer , Prednisone Plus Afuresertib , Following Standard , Alberto Bessudo , Laekna Therapeutics , Chief Medical Officer , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் , ஐரோப்பிய சமூகம் , மருத்துவ புற்றுநோயியல் , மெட்டாஸ்டேடிக் வார்ப்பு எதிர்ப்பு ப்ராஸ்டேட் புற்றுநோய் , தலைமை மருத்துவ அதிகாரி ,

Laekna Therapeutics will present two clinical study results in ESMO 2021

Laekna Therapeutics will present two clinical study results in ESMO 2021
News provided by
Share this article
Share this article
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ Laekna Therapeutics, an emerging innovative pharma company based in China s Zhangjiang Pharma Valley and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced today that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology (ESMO) Congress 2021.
ePoster
Presentation Number: 597P
This
ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC). LAE001 is the first CYP17/CYP11B2 dual inhibitor globally. It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) ....

United States , New Jersey , Cleo Zhang , Leah Liu , Alberto Bessudo Encinitas , European Society For Medical Oncology , European Society , Medical Oncology , Phasei Dose Escalation Study , Prednisone Plus Afuresertib , Metastatic Castration Resistant Prostate Cancer , Following Standard , Alberto Bessudo , Central European Summertime , Laekna Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , கிளியோ ஜாங் , லியா லியூ , ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் , ஐரோப்பிய சமூகம் , மருத்துவ புற்றுநோயியல் , மெட்டாஸ்டேடிக் வார்ப்பு எதிர்ப்பு ப்ராஸ்டேட் புற்றுநோய் ,

Purple Biotech : NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors (Form 6-K)

Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer
REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the tr ....

United States , South Korea , Gil Efron , Bertrandc Liang , Megan Humphreys , Alberto Bessudo , Chuck Padala , Exchange Commission , Company Contact , Purple Biotech Ltd , California Cancer Associates For Research Excellence , Drug Administration , Bristol Myers Squibb , Coeptis Pharmaceuticals , Minimal Adverse Events , Initial Clinical Data , Ongoing Phase , Advanced Solid , Response Observed , Refractory Gastroesophageal Junction , Purple Biotech , California Cancer Associates , Chief Medical Officer , Burke Therapeutics , Looking Statements , Safe Harbor ,